Abstract
Among the isotypes of serum tartrate-resistant acid phosphatase (TRACP), only type 5b (TRACP-5b) is derived from osteoclasts, and it is necessary to develop an assay specific for this TRACP-5b for evaluation of osteoclastic activity. Recently, a novel assay system for TRACP-5b called the fragments absorbed immunocapture enzymatic assay (FAICEA) has been developed. With two unique monoclonal antibodies, one that is highly specific for TRACP-5b and another which absorbs inactive TRACP-5b fragments that interfere with measuring active TRACP-5b, this assay provides correct measurement of TRACP-5b activity in the serum without interference by the inactive fragments of TRACP-5b and other isotypes of TRACP, especially TRACP-5a. To study the reference data of Japanese subjects, we measured TRACP-5b activity in the serum of 320 men (age, 20–82 years) and 466 women [315 premenopausal (age, 18–55 years) and 151 postmenopausal (age, 45–77 years)] with this novel assay. In men, serum TRACP-5b activity did not vary significantly with age. The postmenopausal women had significantly higher serum TRACP-5b activity than the premenopausal women. The reference intervals (logarithmic mean ±1.96 SD) for men, premenopausal women, and postmenopausal women were 1.7–5.9 U/l, 1.2–4.4 U/l, and 2.5–7.6 U/l, respectively.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Uebelhart D, Gineyts E, Chapuy MC, Delmas PD (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87–96
Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked Ntelopeptides in urine. J Bone Miner Res 7:1251–1258
Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C (1994) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022–2025
Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT (1995) Monoclonal antibody assay for measuring bonespecific alkaline phosphatase activity in serum. Clin Chem 41:1560–1566
Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C (1997) Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 12:1028–1034
Clemens JD, Herrick MV, Singer FR, Eyre DR (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058–2063
Lau KH, Onishi T, Wergedal JE, Singer FR, Baylink DJ (1987) Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 33:458–462
Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337–1345
Igarashi Y, Lee MY, Matsuzaki S (2001) Heparin column analysis of serum type 5 tartrate-resistant acid phosphatase isoforms. J Chromatogr B Biomed Sci Appl 757:269–276
Ohashi T, Igarashi Y, Mochizuki Y, Miura T, Inaba N, Katayama K, Tomonaga T, Nomura F (2007) Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 376:205–212
Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139–150
World Health Organization Study Group on Assessment of Fracture Risk and Its Application to Screening and Postmenopausal Osteoporosis (1994) Report of a WHO Study Group. Technical Report Series No. 84. WHO, Geneva
Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M (2005) Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23:97–104
Igarashi Y, Mochizuki Y, Miura T, Ohashi T, Sasagawa K, Katayama K, Inaba N, Matsuzaki S (2003) Evaluation of a novel immunoassay for serum tartrate-resistant acid phosphatase type 5b activity in hormone replacement therapy. Bone (NY) 32:S179
Mochizuki Y, Nishizawa Y, Oishi A, Otsu R, Igarashi Y, Miura T, Inaba N (2005) Day-to-day and diurnal variations of serum tartrate-resistant acid phosphatase type 5b with newly developed TRAP5b kit and their comparison to other bone resorption markers. Bone (NY) 36:S334
Kollerup G, Thamsborg G, Bhatia H, Sorensen OH (1992) Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography. Scand J Clin Lab Invest 52:657–662
Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:1046–1053
Garnero P, Gineyts E, Riou JP, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780–785
Kushida K, Takahashi M, Kawana K, Inoue T (1995) Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80:2447–2450
Khosla S, Atkinson EJ, Melton LJ III, Riggs BL (1997) Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a populationbased study. J Clin Endocrinol Metab 82:1522–1527
Orwoll ES, Bell NH, Nanes MS, Flessland KA, Pettinger MB, Mallinak NJ, Cain DF (1998) Collagen N-telopeptide excretion in men: the effects of age and intrasubject variability. J Clin Endocrinol Metab 83:3930–3935
Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C (1998) Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281–2289
Fatayerji D, Eastell R (1999) Age-related changes in bone turnover in men. J Bone Miner Res 14:1203–1210
Del Campo MT, Gonzalez-Casaus ML, Aguado P, Bernad M, Carrera F, Martinez ME (1999) Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion. Osteoporos Int 9:449–454
Pi YZ, Wu XP, Liu SP, Luo XH, Cao XZ, Xie H, Liao EY (2006) Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women. J Bone Miner Metab 24:380–385
Sone T, Miyake M, Takeda N, Fukunaga M (1995) Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age-and sex-related changes and reference limits. Bone (NY) 17:335–339
Ravn P, Fledelius C, Rosenquist C, Overgaard K, Christiansen C (1996) High bone turnover is associated with low bone mass in both pre-and postmenopausal women. Bone (NY) 19:291–298
Ravn P, Rix M, Andreassen H, Clemmesen B, Bidstrup M, Gunnes M (1997) High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Calcif Tissue Int 60:255–260
Melton LJ III, Khosla S, Atkinson EJ, O’Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091
Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 14:1583–1595
Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD (2001) Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16:1642–1650
Chu P, Chao TY, Lin YF, Jankila AJ, Yam LT (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 41:1052–1059
WHO Scientifi c Group (2003) Prevention and management of osteoporosis. WHO Technical report series 921. WHO, Geneva
The committee for establishing the guideline for initiating pharmacologic treatment to prevent fragility fractures (2006) The guideline for initiating pharmacologic treatment to prevent fragility fractures (in Japanese). Osteoporosis Jpn 14:665–668
Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int Suppl 6:S55–S65
Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone (NY) 34:187–194
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Nishizawa, Y., Inaba, M., Ishii, M. et al. Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab 26, 265–270 (2008). https://doi.org/10.1007/s00774-007-0826-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-007-0826-0